Placental membrane dressings to speed healing of diabetic foot ulcers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 4 interventional study applies placental membrane dressings to eligible diabetic foot ulcers alongside standard wound care. Eligible ulcers are Wagner Grade I or II, located below the malleoli, measure 1.0–20.0 cm2 after debridement, and have been present 4 weeks to 12 months with <30% reduction on standard care; wound area is measured with an eKare device. Participants are treated and followed at outpatient sites in Phoenix or Houston to track wound-size change and time to closure. The trial tests real-world healing outcomes for a marketed placental membrane product.

Why it matters

Who can join: the full rules

Inclusion Criteria.

1. Patient has signed the informed consent form.
2. Male or female patient at least 18 years of age or older, as of the date of the screening visit.
3. Confirmed diagnosis of Type 1 or Type 2 DM.
4. Has a DFU that is located below the malleoli ranging in size from 1.0 cm2 to 20.0 cm2, post debridement, when measured by the investigator staff at the screening visit using the eKare device.
5. The DFU has been present for ≥4 weeks and ≤12 months.
6. The DFU is non-healing as defined as \<30% reduction in size in response to standard of care from Screening (Visit 1) to Study Day 1 (Visit 2).
7. If more than one ulcer is present the selected target ulcer must be at least 2 cm from the nearest edge of any adjacent ulcers.
8. The depth of the target foot ulcer is graded as Wagner Grade I or II, i.e., with no evidence of exposed muscle, tendon, bone, or joint capsule.
9. Arterial supply adequacy to the foot with the target ulcer confirmed by any one of the following and documented in medical record/EMR:

   1. Great toe pressure ≥ 40 mm/Hg
   2. Systolic blood pressure Ankle Brachial Index (ABI) in the range ≥ 0.70 ≤ 1.20
   3. TcPO2 ≥ 30 mmHg from the foot
   4. Toe Brachial Index or TBI ≥ 0.65
10. Willing to follow all instructions given by the Investigator, return for all visits, and adhere to off-loading protocols while on the study.

Exclusion Criteria

1. Hemoglobin A1c (HbA1c) level is \> 10%.
2. Chronic oral steroid use of \> 7.5 mg daily within the previous 30 days preceding screening.
3. Chronic oral or parenteral corticosteroids, or any cytotoxic agents within the previous 30 days preceding screening.
4. Has tested positive for Human Immunodeficiency Virus (HIV) or has Acquired Immune Deficiency Syndrome (AIDS).
5. Has malignancy or history of cancer in 5 years preceding the screening visit other than non- melanoma skin cancer.
6. Pregnant or lactating women.
7. Women of child-bearing potential who are unwilling to avoid pregnancy or use an effective form of birth control.
8. Currently on dialysis or planning to start dialysis.
9. Is currently enrolled or participated in another device, drug, or biological trial within 30 days of screening.
10. Has used wound treatments with enzymes, growth factors, living skin, dermal substitutes including other amniotic or umbilical cord tissue therapies, or other advanced biological therapies within the last 30 days.
11. Current use of topical anti-microbial or silver-containing products.
12. Target ulcer is over an active or inactive Charcot deformity.
13. The depth of the target ulcer is graded as Wagner Grade III or higher, i.e., with evidence of exposed muscle, tendon, bone, and/or joint capsule.
14. Gangrene is present on any part of the affected foot.
15. Current suspicion of osteomyelitis, cellulitis, or other clinical signs or symptoms of target ulcer infection.
16. Any previous use of human placental membrane applied to the target ulcer.

Where it's running

• Axsendo
  Phoenix, Arizona, United States Recruiting
• Axsendo Clinical Research
  Houston, Texas, United States Recruiting

Study contacts

• Study coordinator: Josh Arnold
• Email: Josh.Arnold@Purity-Health.com
• Phone: 302-604-4532

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Differentiating heart disease in autoimmune vs. type 2 diabetes

  This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.

  Recruiting University of Roma La Sapienza · Rome, Roma · NCT07911007

• High BMI and periodontitis in Thai adults under 60

  This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.

  Recruiting Mahidol University · Bangkok, Ratchathewi · NCT07880717

• Reset-INSPIRE: See if CGM can reveal insulin sensitivity in people at risk for MASLD

  This study tests whether real-time CGM data can accurately reflect insulin sensitivity in adults without diabetes who are at risk for MASLD.

  Recruiting National University Health System, Singapore · Singapore, Singapore · NCT07861191

• Telemonitoring for Better Glycemic Control in Tunisian Adults with Diabetes

  This trial tests whether remote diabetes management through a mobile app and web platform can improve blood sugar control in adults with diabetes in Tunisia compared with standard care.

  Recruiting University of Monastir · Monastir · NCT07774078

• Rapid guideline-based therapy after a heart attack

  This project tests whether starting guideline-driven secondary prevention soon after a heart attack helps people who had PCI reach better risk-factor control and fewer heart events.

  Recruiting Zuyderland Medisch Centrum · Heerlen, Limburg · NCT07773272

• Impact of a Clinical Information System on hospital outcomes for adults with chronic diseases

  This study tests whether implementing a Clinical Information System helps reduce readmissions or death within 30 days after hospital discharge for adults with chronic conditions in Alberta.

  Recruiting University of Calgary · Calgary, Alberta · NCT07609381

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.